About this trial
Despite substance use causing significant harms and cost to our health care system, British Columbia's (BC) current addiction treatment system remains under-resourced and fragmented. To address this, Providence Health Care (PHC) is expanding clinical addiction services as part of the Road to Recovery Initiative (R2R). The proposed study aims to generate novel data to promote fully evidence-informed and coordinated substance use care in BC and beyond. This study will explore substance use treatment trajectories, identify challenges and areas for growth in addiction health services, characterize important features of patients accessing care, and improve our provincial capacity to promptly tailor approaches to care in response to the substance use crisis.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Aged 18 years or older
Able to provide written informed consent
A resident of British Columbia
Willing to comply with study procedures
Disqualifiers
Individuals who have an acute, severe mental health condition (e.g., psychosis) precluding the opportunity to provide full informed consent
Individuals who have an acute, severe medical condition (e.g., intubation) precluding the opportunity to provide full informed consent
Trial population
People who have accessed or been admitted to any R2R service.
Trial design
Cohort
Prospective
Treatments tested in this trial
Specialized clinical service access
Other interventionA new model of addiction care that will offer comprehensive and coordinated service delivery
Treatment groups
Trial outcomes
Primary outcomes
Substance use patterns following R2R access
Metrics include frequency of use in the 12-months following R2R access
Health care utilization patterns following R2R access
Metrics include the count of hospitalizations, readmissions, and emergency department visits.
Substance use treatment trajectories
Metrics include completion status of substance use treatment programs within 12 months after R2R access.
Health among study participants over time
Metrics include count of comorbidities in the 12 months following R2R access.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.